tiprankstipranks
Advertisement
Advertisement

HK:2509 Stock Latest News

Qyuns Therapeutics Wins New QX027N Trial Approvals and Secures Global Licensing Deal
Company AnnouncementsQyuns Therapeutics Wins New QX027N Trial Approvals and Secures Global Licensing Deal
5d ago
2509
Caldera-Synlogic Merger and $278 Million Raise Bolster Qyuns-Linked IBD Program
PremiumCompany Announcements
Caldera-Synlogic Merger and $278 Million Raise Bolster Qyuns-Linked IBD Program
7d ago
2509
Qyuns Therapeutics to Fully Acquire Cellularforce in RMB86 Million Connected Deal
PremiumCompany Announcements
Qyuns Therapeutics to Fully Acquire Cellularforce in RMB86 Million Connected Deal
1M ago
2509
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
PremiumCompany Announcements
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
2M ago
2509
Qyuns Therapeutics Shareholders Unanimously Approve AGM Resolutions
PremiumCompany Announcements
Qyuns Therapeutics Shareholders Unanimously Approve AGM Resolutions
2M ago
2509
Qyuns Therapeutics Hits Roche Milestone as QX031N Enters Phase I Trial
PremiumCompany AnnouncementsQyuns Therapeutics Hits Roche Milestone as QX031N Enters Phase I Trial
2M ago
2509
Qyuns Therapeutics Wins China Approval for Ustekinumab in Crohn’s Disease
Premium
Company Announcements
Qyuns Therapeutics Wins China Approval for Ustekinumab in Crohn’s Disease
3M ago
2509
Qyuns Therapeutics Sets 2025 AGM to Approve Reports, Profit Plan and Share Issuance Mandate
Premium
Company Announcements
Qyuns Therapeutics Sets 2025 AGM to Approve Reports, Profit Plan and Share Issuance Mandate
3M ago
2509
Qyuns Therapeutics Invests RMB270 Million in Low-Risk PDB Wealth Products
PremiumCompany Announcements
Qyuns Therapeutics Invests RMB270 Million in Low-Risk PDB Wealth Products
3M ago
2509
Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
PremiumCompany Announcements
Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
4M ago
2509
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
PremiumCompany Announcements
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
4M ago
2509
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
PremiumCompany Announcements
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
4M ago
2509
Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
PremiumCompany AnnouncementsQyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
4M ago
2509
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
Premium
Company Announcements
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
4M ago
2509
Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
Premium
Company Announcements
Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
4M ago
2509
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
PremiumCompany Announcements
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
5M ago
2509
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
PremiumCompany Announcements
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
5M ago
2509
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
PremiumCompany Announcements
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
6M ago
2509
Qyuns Steps Up IBD Push as Caldera Raises US$112.5 Million and Starts Phase I Trial of Bispecific Antibody
PremiumCompany Announcements
Qyuns Steps Up IBD Push as Caldera Raises US$112.5 Million and Starts Phase I Trial of Bispecific Antibody
7M ago
2509
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
PremiumCompany AnnouncementsQyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
7M ago
2509
Qyuns Therapeutics Out-Licenses QX027N Globally in Deal Worth Up to US$700 Million
Premium
Company Announcements
Qyuns Therapeutics Out-Licenses QX027N Globally in Deal Worth Up to US$700 Million
8M ago
2509
Qyuns Therapeutics Shareholders Approve Renewal of Caps for Connected Transactions at EGM
Premium
Company Announcements
Qyuns Therapeutics Shareholders Approve Renewal of Caps for Connected Transactions at EGM
8M ago
2509

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >